Sanofi SA vs Suncor Energy Inc. — how do they compare? Sanofi SA trades at $40.1 (market cap $96.81B), while Suncor Energy Inc. trades at $70.57 (market cap $80.03B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Suncor Energy Inc. for 57 Days on average.
| SNY | SU | |
|---|---|---|
Market Cap | $96.81B | $80.03B |
Volume | 2,081,815 | 2,907,827 |
Sector | Health | Energy |
52-Week High | $52.34 | $71.87 |
52-Week Low | $39.51 | $38.17 |
Typical Hold Time | 94 Days | 57 Days |
Enterprise Value | $116.20B | $86.58B |
Dividend Yield | 6.02% | 2.49% |
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Suncor Energy (SU) trades at $70.91, up 3.94% today, reflecting strong momentum near recent highs. The stock exhibits a bullish technical trend with support at $68 and resistance at $69. Fundamentally, SU maintains solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 12.98. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Cash flow remains robust, supporting shareholder returns via buybacks.
The outlook for SU is positive, driven by strong cash generation, debt reduction, and strategic asset sales. Investment appeal lies in its integrated model, shareholder returns, and exposure to global energy markets. Key risks include commodity price volatility, operational disruptions from weather, and execution of leadership transition. Analyst consensus is strongly bullish with 74% buy ratings, signaling confidence in continued performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →